A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following extraction of impacted third molar tooth

Trial Profile

A randomised, double blind, placebo and active controlled, parallel group study to evaluate the analgesic effect of a single dose of GRC 6211, a TRPV1 receptor antagonist on pain following extraction of impacted third molar tooth

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs GRC 6211; Ibuprofen
  • Indications Dental pain
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals S.A.
  • Most Recent Events

    • 18 May 2011 New source identified and integrated.
    • 05 Jun 2007 The expected completion date for this trial is now 1 Dec 2007.
    • 28 May 2007 Status changed from planning to initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top